Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|October 25, 2017
What Economic Impact will Biosimilars Have in Health Care?
Grant Knowles, PharmD, vice president, Business Development, Ardon Health, discusses the potential impact biosimilars will have in health care.
Advertisement
Knowles: I think any time you introduce competition into an environment, there's a lot of opportunities for economic gains--they can be positive, they can be negative. I think it will be interested to watch to see as biosimilars are launched and see the traction with health plans and pharmacies.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5